Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1284-1292

  Bosnyák, Edit ^a,c   Kamson, David O ^a,c   Guastella, Anthony R ^a   Varadarajan, Kaushik ^a   Robinette, Natasha L ^b,d   Kupsky, William J ^a,d   Muzik, Otto ^a,b,c   Michelhaugh, Sharon K ^a   Mittal, Sandeep ^a,d   Juhász, Csaba ^a,c,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

glioma; indoleamine 2,3 dioxygenase (IDO); meningioma; positron emission tomography (PET); tryptophan 2,3 dioxygenase (TDO)

Indexed keywords

ALPHA [11C] METHYL LEVO TRYPTOPHAN; ENZYME; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE 2; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KINETICS; MALE; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; TRYPTOPHAN METABOLISM; TUMOR DIFFERENTIATION; TUMOR/CORTEX RATIO; ANALOGS AND DERIVATIVES; BRAIN; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN; CHILD; FEMALE; GLIOMA; HUMANS; KYNURENINE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION; TRYPTOPHAN; YOUNG ADULT;

EID: 84937047516     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov098     Document Type: Article

References (50)

1. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314.
2. Yano S, Kuratsu J, Kumamoto Brain Tumor Research Group. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006;105(4): 538-543.
3. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics. 2009; 6(3):465-477.
4. Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am. 2003;11(3):415-429.
5. 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55(4):540-545.
6. 1H-MRS of intracranial meningiomas: what it can add to known clinical and MRI predictors of the histopathological and biological characteristics of the tumor? Clin Neurol Neurosurg. 2011;113(3):202-212.
7. Harting I, Hartmann M, Bonsanto MM, et al. Characterization of necrotic meningioma using diffusion MRI, perfusion MRI, and MR spectroscopy: case report and review of the literature. Neuroradiology. 2004;46(3):189-193.
8. Jain A, Hoeprich M, Mittal M, et al. Spontaneous intratumoral infarction - an unusual evolution of a falcine meningioma. Clin Neuropathol. 2014;33(6):412-417.
9. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9(9):906-920.
10. Zhang H, Rodiger LA, Shen T, et al. Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology. 2008;50(6):525-530.
11. Sanverdi SE, Ozgen B, Oguz KK, et al. Is diffusion-weighted imaging useful in grading and differentiating histopathological subtypes of meningiomas? Eur J Radiol. 2012;81(9):2389-2395.
12. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468-1481.
13. 18F-fluoro-L-tyrosine: initial report. J Nucl Med. 2007;48(9):720-725.
14. Ikeda H, Tsuyuguchi N, Kunihiro N, et al. Analysis of progression and recurrence of meningioma using (11)C-methionine PET. Ann Nucl Med. 2013;27(8):772-780.
15. Alkonyi B, Mittal S, Zitron I, et al. Increased tryptophan transport in epileptogenic dysembryoplastic neuroepithelial tumors. J Neurooncol. 2012;107(2):365-372.
16. Juhasz C, Nahleh Z, Zitron I, et al. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl Med Biol. 2012;39(7):926-932.
17. Haining Z, Kawai N, Miyake K, et al. Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol. 2012;12:4.
18. Diksic M, Nagahiro S, Sourkes TL, et al. A new method to measure brain serotonin synthesis in vivo. I. Theory and basic data for a biological model. J Cereb Blood Flow Metab. 1990;10(1):1-12.
19. Chugani DC, Muzik O. Alpha[C-11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab. 2000;20(1):2-9.
20. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J Clin Invest. 2007;117(5):1147-1154.
21. Batista CE, Juhasz C, Muzik O, et al. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol Imaging Biol. 2009;11(6):460-466.
22. Miyazaki T, Moritake K, Yamada K, et al. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation. J Neurosurg. 2009;111(2):230-237.
23. Wainwright DA, Balyasnikova IV, Chang AL, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22): 6110-6121.
24. 11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab. 2006;26(3):345-357.
25. 11C]methyl-L-tryptophan on PET in low-grade brain tumors. J Neurooncol. 2011;102(3):409-415.
26. 11C-methyl-L-tryptophan PET. J Nucl Med. 2012;53(7): 1058-1064.
27. Juhasz C, Chugani DC, Barger GR, et al. Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity. Clin Nucl Med. 2012; 37(9):838-842.
28. Kamson DO, Mittal S, Robinette NL, et al. Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma. Neuro Oncol. 2014;16(10):1373-1383.
29. Zitron IM, Kamson DO, Kiousis S, et al. In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer Biol Ther. 2013;14(4):333-339.
30. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197-203.
31. Austin CJ, Rendina LM. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today. 2015;20(5): 609-617.
32. 11C]methyl-L-tryptophan. Nucl Med Biol. 1996;23(8):1005-1008.
33. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1-7.
34. Juhasz C, Muzik O, Lu X, et al. Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med. 2009;50(3):356-363.
35. Muzik O, Chugani DC, Chakraborty P, et al. Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo. J Cereb Blood Flow Metab. 1997; 17(6):659-669.
36. Juhasz C, Dwivedi S, Kamson DO, et al. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging. 2014;13: doi:10.2310/7290.2014.00015.
37. Kikinis R, Pieper S. 3D Slicer as a tool for interactive brain tumor segmentation. Conf Proc IEEE Eng Med Biol Soc. 2011;2011: 6982-6984.
38. Mattes D, Haynor DR, Vesselle H, et al. PET-CT image registration in the chest using free-form deformations. IEEE Trans Med Imaging. 2003;22(1):120-128.
39. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
40. 18F-fluorodeoxy glucose positron-emission tomography. J Neurooncol. 2012; 107(2):379-386.
41. Iuchi T, Iwadate Y, Namba H, et al. Glucose and methionine uptake and proliferative activity in meningiomas. Neur Res. 1999;21(7):640-644.
42. 18F-FDG PET. Eur J Nucl Med Imaging. 2002;29(2):176-182.
43. Cornelius JF, Stoffels G, Filss C, et al. Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results. Eur J Nucl Med Imaging. 2015;42(3):459-467.
44. Cornelius JF, Langen KJ, Stoffels G, et al. Positron emission tomography imaging of meningioma in clinical practice: review of literature and future directions. Neurosurgery. 2012;70(4):1033-1041.
45. 11C-methionine-PET. J Neurooncol. 2012;109(1): 115-122.
46. Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and misleading features in meningioma. Radiographics. 1991;11(6): 1087-1106.
47. Kremer S, Grand S, Remy C, et al. Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol. 2002;29(2):105-113.
48. 18F] 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximid amide (IDO5L): a novel potential PET probe for imaging of IDO1 expression. J Labelled Comp Radiopharm. 2015;58(4): 156-162.
49. 18F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging. Eur J Med Chem. 2013; 70:768-780.
50. Chiotellis A, Muller A, Mu L, et al. Synthesis and biological evaluation of (18)F-labeled Fluoroethoxy tryptophan analogues as potential PET tumor imaging agents. Mol Pharm. 2014; 11(11):3839-3851.